Value Creation – Alternative (VC-A) is pleased to announce a new partnership with You Are Capital (YAC) to launch the VDD Fund, a dedicated investment vehicle designed to pre-finance Vendor Due Diligence (VDD) in M&A transactions. The teaser will be available for download directly from the website. The fund concept and teaser position this as...
Category: Mergers & Adquisitions
Argos Index Q4 2025: Valuations Decline to 8.3x EBITDA — A Turning Point for Mid-Market M&A
The Argos Index® Q4 2025, which tracks quarterly valuation levels of private mid-market companies in the eurozone, has just been released. Valuations continue their downward adjustment, reaching 8.3x EBITDA, the lowest level observed since 2014. This ongoing correction reflects a structural shift in negotiating dynamics and is beginning to unlock renewed activity in the mid-market...
300+ Sell-Sides – Exclusive for VC-A Members
Value Creation – Alternative (VC-A) has entered a strategic partnership with a leading US-based M&A platform, providing privileged access to 300+ active sell-side mandates (SMEs and mid-market). This complements VC-A’s existing proprietary dealflow sourced through our global network of 1,200+ Members. Those sell-side mandates are exclusive to VC-A Members. If you are not yet a...
Argos Index Q3 2025: European SME prices down further to 8.7x EBITDA, the lowest level since 2017
The Q3 2025 Argos Index®, measuring every quarter the level of private mid-market company valuations in the euro zone, has been released. The index is further down to 8.7x EBITDA, a decline affecting all segments of the mid-market. Please click here to download the complete study.
Argos Index Q2 2025: European SME prices continue their downward slide to 9.2x EBITDA
The Q2 2025 Argos Index®, measuring every quarter the level of private mid-market company valuations in the euro zone, has been released. The index is down to 9.2x EBITDA, reflecting widespread uncertainty that disrupted the European mid-market M&A activity. Please click here to download the complete study.